Supergene, LLC

Industry · 9 registered clinical trials — 4 currently recruiting.

Status	Trial	Phase	Started
Not Yet Recruiting	Single Bolus Non-immunogenic Staphylokinase in Patients With Acute Ischemic Stroke Within 4.5-24 Hours of Symp Ischemic Stroke, Acute	Phase 3	2026-02-01
Recruiting	Post-registration Trial of the Non-immunogenic Staphylokinase in Massive Pulmonary Embolism Pulmonary Embolism Acute Massive	—	2025-06-01
Recruiting	Non-immunogenic Recombinant Staphylokinase vs Placebo in Patients With Intermediate High-risk Pulmonary Emboli Pulmonary Embolism	Phase 3	2024-05-23
Recruiting	Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia F Acute Limb Ischemia	Phase 3	2022-12-26
Terminated	Inhaled Recombinant Non-immunogenic Staphylokinase vs Placebo in Patients With COVID-19 - FORRIF Trial COVID-19	Phase 2 / Phase 3	2021-12-27
Completed	Post-registration Trial of the Non-immunogenic Staphylokinase in Acute Ischemic Stroke (FORPI Registry) Acute Ischemic Stroke	—	2021-03-01
Completed	Massive Pulmonary Embolism: Trial of Non-immunogenic Recombinant Staphylokinase VS Alteplase FORPE Massive Pulmonary Embolism	Phase 3	2020-12-15
Completed	Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients W Ischemic Stroke	Phase 3	2017-03-18
Completed	Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI Myocardial Infarction	Phase 3	2014-05-16